New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication

被引:91
作者
Hernandez-Alcoceba, R [1 ]
Pihalja, M [1 ]
Qian, DL [1 ]
Clarke, MF [1 ]
机构
[1] Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA
关键词
D O I
10.1089/104303402760293574
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Oncolytic adenoviruses with restricted replication can be produced if the expression of crucial transcription units of the virus is controlled by tissue-or tumor-specific promoters. Here we describe a method for the rapid incorporation of exogenous promoters into the E1A and E4 regions of the human adenovirus type 5 genome. Using this system, we have generated AdEHT2 and AdEHE2F, two conditionally replicative adenoviruses for the treatment of breast cancer. The expression of the E1A gene in both viruses is controlled by a minimal dual-specificity promoter that responds to estrogens and hypoxia. The tight regulation of E1A expression correlated with the ability of these viruses to replicate and kill human cancer cells that express estrogen receptors, or are maintained under hypoxic conditions. The telomerase reverse transcriptase (TERT) promoter and the E2F-1 promoter are preferentially activated in cancer cells. They were introduced into the E4 region of AdEHT2 and AdEHE2F, respectively. The telomerase core promoter failed to block the replication of the virus in telomerase-negative cells. In contrast, AdEHE2F was attenuated in nontransformed quiescent cells growing under normoxic conditions, suggesting that an intact pRB pathway with low levels of E2F transcription factors acts as a negative modulator for the virus. These data indicate that the simultaneous regulation of E1A and E4 viral transcription units by the appropriate combination of promoters can increase the tumor selectivity of oncolytic adenoviruses.
引用
收藏
页码:1737 / 1750
页数:14
相关论文
共 57 条
[1]  
Adachi Y, 2001, CANCER RES, V61, P7882
[2]   Replicative adenoviruses for cancer therapy [J].
Alemany, R ;
Balagué, C ;
Curiel, DT .
NATURE BIOTECHNOLOGY, 2000, 18 (07) :723-727
[3]   Replication-selective viruses for cancer therapy [J].
Biederer, C ;
Ries, S ;
Brandts, CH ;
McCormick, F .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2002, 80 (03) :163-175
[4]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[5]   Levels of hypoxia-inducible factor-1α during breast carcinogenesis [J].
Bos, R ;
Zhong, H ;
Hanrahan, CF ;
Mommers, ECM ;
Semenza, GL ;
Pinedo, HM ;
Abeloff, MD ;
Simons, JW ;
van Diest, PJ ;
van der Wall, E .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) :309-314
[6]   The role of adenovirus E4orf4 protein in viral replication and cell killing [J].
Branton, PE ;
Roopchand, DE .
ONCOGENE, 2001, 20 (54) :7855-7865
[7]   Expression of MUC-1 epitopes on normal bone marrow:: Implications for the detection of micrometastatic tumor cells [J].
Brugger, W ;
Bühring, HJ ;
Grünebach, F ;
Vogel, W ;
Kaul, S ;
Müller, R ;
Brümmendorf, TH ;
Ziegler, BL ;
Rappold, I ;
Brossart, P ;
Scheding, S ;
Kanz, L .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1535-1544
[8]   Targeting gene expression to hypoxic tumor cells [J].
Dachs, GU ;
Patterson, AV ;
Firth, JD ;
Ratcliffe, PJ ;
Townsend, KMS ;
Stratford, IJ ;
Harris, AL .
NATURE MEDICINE, 1997, 3 (05) :515-520
[9]   Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy [J].
Doronin, K ;
Kuppuswamy, M ;
Toth, K ;
Tollefson, AE ;
Krajcsi, P ;
Krougliak, V ;
Wold, WSM .
JOURNAL OF VIROLOGY, 2001, 75 (07) :3314-3324
[10]   Determinants of ligand specificity of estrogen receptor-α:: Estrogen versus androgen discrimination [J].
Ekena, K ;
Katzenellenbogen, JA ;
Katzenellenbogen, BS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (02) :693-699